Název:
Hybrid organometallic galectin inhibitors
Autoři:
Hamala, Vojtěch Typ dokumentu: Příspěvky z konference Konference/Akce: Bažant Postgraduate Conference 2022, Prague (CZ), 20220613
Rok:
2022
Jazyk:
eng
Abstrakt: Galectins are lectin-type proteins defined by their sequence homology and the ability to bind β-galactosides. Human galectin-1 (Gal-1) and galectin-3 (Gal-3) are involved in tumor progression. Elevated Gal-1 levels are reported for many tumor tissues and Gal-1 contributes to tumor progression including cell migration and tumor immune escape.\nGal-3 is characteristically overexpressed in many cancers and an elevated Gal-3 level is associated with increased invasiveness, metastatic spreading, immunosuppression and angiogenesis. Galectins are also implicated in progression of serious diseases other than cancer e.g., cardiovascular ones, diabetes mellitus, fibrosis, and others. These\nproperties make galectins promising therapeutic targets.\n
Klíčová slova:
galectin inhibitors; glycomymetics; organometallic compounds Zdrojový dokument: Proceedings of Abstracts, ISBN 978-80-86186-24-5
Práva: Dílo je chráněno podle autorského zákona č. 121/2000 Sb.